Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;2003(1):CD003361.
doi: 10.1002/14651858.CD003361.

Beta-blocker therapy for tremor in Parkinson's disease

N J Crosby  1 , K H O Deane, C E Clarke
Affiliations

Beta-blocker therapy for tremor in Parkinson's disease

N J Crosby et al. Cochrane Database Syst Rev. 2003.

Abstract

Background: The tremor of Parkinson's disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as Essential Tremor or the tremor associated with anxiety. It is thought that beta-blockers may be of use in controlling the tremor of Parkinson's disease.

Objectives: To compare the efficacy and safety of adjuvant beta-blocker therapy against placebo for the treatment of tremor in patients with Parkinson's disease.

Search strategy: Electronic searches of MEDLINE, EMBASE, SCISEARCH, BIOSIS, GEROLIT, OLDMEDLINE, LILACS, MedCarib, PASCAL, JICST-EPLUS, RUSSMED, DISSERTATION ABSTRACTS, SIGLE, ISI-ISTP, Aslib Index to Theses, The Cochrane Controlled Trials Register, Clinicaltrials.gov, metaRegister of Controlled Trials, NIDRR, NRR and CENTRAL were conducted. Grey literature was hand searched and the reference lists of identified studies and reviews examined. The manufacturers of beta-blockers were contacted.

Selection criteria: Randomised controlled trials of adjuvant beta-blocker therapy versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease.

Data collection and analysis: Data was abstracted independently by two of the authors onto standardised forms and disagreements were resolved by discussion.

Main results: Four randomised controlled trials were found comparing beta-blocker therapy with placebo in patients with idiopathic Parkinson's disease. These were double-blind cross-over studies involving a total of 72 patients. Three studies did not present data from the first arm, instead presenting results as combined data from both treatment arms and both placebo arms. The risk of a carry-over effect into the second arm meant that these results were not analysed. The fourth study presented data from each arm. This was in the form of a mean total score for tremor for each group. Details of the baseline scores, the numbers of patients in each group and standard deviations were not provided, meaning that the magnitude and significance of any changes due to therapy could not be calculated. One study reported a substantial fall in heart rate in 14 of the 22 patients, with one patient withdrawing after his heart rate dropped to 56 beats per minute (baseline heart rate was not reported).

Reviewer's conclusions: In view of this lack of evidence, it is impossible to determine whether beta-blocker therapy is effective and safe for the treatment of tremor in Parkinson's disease. The high frequency of bradycardia in one trial raises some concerns about the prescription of beta-blockers to normotensive elderly patients but the study was too small for the true degree of risk to be calculated.

PubMed Disclaimer

Conflict of interest statement

None.

References

References to studies included in this review

Claveria 75 {published data only}
    1. Claveria LE, Vakil SD, George CF, Reid JL, Calne DB, Petrie A. Oxprenolol in Parkinsonism. The Journal of Clinical Pharmacology 1975;15(1):66‐68.
Corbett 76 {published data only}
    1. Corbett JL. Efficacy of Oxprenolol in the Treatment of Essential and Parkinsonian Tremor ‐ a Description of Two Controlled Trials and a Review of the Literature. In: Kielkholz P editor(s). Beta Blockers And The Central Nervous System. An International Symposium. Bern: Huber, 1976:200‐217.
Henderson 94 {published data only}
    1. Henderson JM, Yiannikas C, Morris JG, Einstein R, Jackson D, Byth K. Postural tremor of Parkinson's disease. Clinical Neuropharmacology 1994;17(3):277‐285. - PubMed
Marsden 74 {published data only}
    1. Marsden CD, Parkes JD, Rees JE. Propranolol in Parkinson's disease. Lancet 1974;2(7877):410. - PubMed

References to studies excluded from this review

Abramsky 71 {published data only}
    1. Abramsky O, Carmon A, Savy S. Combined treatment of parkinsonian tremor with propranolol and levodopa. Journal of Neurological Science 1971;14:491. - PubMed
Chaturvedi 87 {published data only}
    1. Chaturvedi SK. Metoprolol in the treatment of neuroleptic‐induced tremor: case report. The Journal of Clinical Psychiatry 1987;48(9):378. - PubMed
Dowzenko 76 {published data only}
    1. Dowzenko A, Buksowicz C, Kuran W. Effect of Coretal Polfa (Oxprenolol) on parkinsonian tremor and benign essential tremor. Neurol Neurochir Pol 1976;10(1):49‐53. - PubMed
Floru 71 {published data only}
    1. Floru L. Clinical treatment of lithium induced tremors with a beta receptor antagonist (propranolol). Int Pharmacopsychiatry 1971;6(4):197‐222. - PubMed
Garcia‐Talavera 85 {published data only}
    1. Garcia‐Talavera FB, Diaz MR, Paz yAP. Atenolol in the control of parkinsonian tremor [Atenolol en el control del trmblor parkinsoniano]. Medicinia Clinica 1985;84(2):78‐79. - PubMed
Gilligan 72 {published data only}
    1. Gilligan BS, Veale JL, Wodak J. Propranolol in the treatment of tremor. Medical Journal of Australia 1972;59(I):1455 (corresp). - PubMed
Henderson 95 {published data only}
    1. Henderson JM, Einstein R, Jackson DM, Byth K, Morris JG. 'Atypical' tremor. European Neurology 1995;35:321‐326. - PubMed
Jackson 71 {published data only}
    1. Jackson R, Crawford CO, Peel JS. Oxprenolol in Parkinson's disease. New Zealand Medical Journal 1971;74:246. - PubMed
Kissel 74 {published data only}
    1. Kissel P, Tridon P, Andre JM. [Levodopa‐propranolol therapy in parkinsonian tremor]. The Lancet 1974:403‐404. - PubMed
Koller 87 {published data only}
    1. Koller WC, Herbster G. Adjuvant therapy of Parkinsonian tremor. Archives of Neurology 1987;44:921‐923. - PubMed
Metzer 93 {published data only}
    1. Metzer WS, Paige SR, Newton JE. Inefficacy of propranolol in attenuation of drug‐induced parkinsonian tremor. Movement Disorders 1993;8(1):43‐46. - PubMed
Owen 65 {published data only}
    1. Owen DA, Marsden CD. Effect of adrenergic beta‐blockade on parkinsonian tremor. Lancet 1965;2(7425):1259‐1262. - PubMed
Sandler 75 {published data only}
    1. Sandler M, Fellows LE, Calne DB, Findley LJ. Oxprenolol and levodopa in parkinsonian patients. Lancet 1975;I:168 (corresp). - PubMed
Strang 65 {published data only}
    1. Strang RR. Clinical trial with a beta‐receptor antagonist (propanolol) in Parkinsonism. Journal of Neurology, Neurosurgey and Psychiatry 1965;28:404‐406. - PMC - PubMed
Takahashi 88 {published data only}
    1. Takahashi A, Indo T. Clinical application in tremor due to essential tremor and Parkinson's disease ‐ Focus on Inderal treatment. Diagnosis and Treatment 1988;76(12):3007‐3012.
Vas 66 {published data only}
    1. Vas C J. Propanolol in parkinsonian tremor. The Lancet 1966:182‐183. - PubMed

Additional references

CONSORT 2001
    1. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomised trials. The Lancet 2001;357:1191‐1194. - PubMed
Gibb 88
    1. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 1988;51:745‐752. - PMC - PubMed
Gleiter 1996
    1. Gleiter CH, Deckert J. Adverse CNS‐effects of beat‐andrenoceptor blockers. Pharmacopsychiatry 1996;29(6):201‐211. - PubMed
Hoehn 67
    1. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17(5):427‐442. - PubMed
Jankovic 80
    1. Jankovic J, Fahn S. Physiologic and pathologic tremors. Annals of Internal Medicine 1980;93(3):460‐465. - PubMed
Koller 84
    1. Koller WC. Diagnosis and treatment of tremors. Neurologic Clinics 1984;2(3):499‐514. - PubMed
Rajput 91
    1. Rajput AH, Rozdilsky B, Ang L. Occurence of resting tremor in Parkinson's disease. Neurology 1991;41(8):1298‐1299. - PubMed
Uitti 1998
    1. Uitti RJ. Medical treatment of Essential Tremor and Parkinson's disease. Geriatrics 1998;53(5):46‐8, 53‐7. - PubMed

Publication types

MeSH terms

Substances